What is he best known for?
The fields of study he is best known for:
- Gene
- Immune system
- Cancer
Lieping Chen mainly focuses on Immunology, Immune system, Antigen, T cell and Cell biology.
His Immunology research includes elements of Cancer and Blockade.
The study incorporates disciplines such as Stromal cell and Downregulation and upregulation in addition to Immune system.
His Antigen study incorporates themes from Cancer cell, Inflammation and Monoclonal antibody.
His study in T cell is interdisciplinary in nature, drawing from both Cytotoxic T cell, Dendritic cell, Macrophage and Immune tolerance.
His Cell biology study combines topics from a wide range of disciplines, such as Receptor, Cytokine, Avidity and Molecular biology.
His most cited work include:
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. (8133 citations)
- Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. (3925 citations)
- Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion (3453 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Immunology, Immune system, T cell, Cancer research and Cytotoxic T cell.
His study ties his expertise on Cancer together with the subject of Immunology.
His Cancer research integrates issues from Melanoma and Oncology.
His research in Immune system intersects with topics in Inflammation, Cytokine and Monoclonal antibody.
The T cell study combines topics in areas such as Molecular biology, In vitro, Immune tolerance and Cell biology.
His work in Cancer research addresses subjects such as Tumor necrosis factor alpha, which are connected to disciplines such as Interferon gamma.
He most often published in these fields:
- Immunology (56.76%)
- Immune system (41.19%)
- T cell (31.35%)
What were the highlights of his more recent work (between 2015-2021)?
- Cancer research (26.64%)
- Immune system (41.19%)
- Immunology (56.76%)
In recent papers he was focusing on the following fields of study:
Lieping Chen spends much of his time researching Cancer research, Immune system, Immunology, Cancer and Immunotherapy.
His studies deal with areas such as Cytotoxic T cell, Cell, CD8 and T cell as well as Cancer research.
The various areas that Lieping Chen examines in his Immune system study include Receptor, Antibody, Monoclonal antibody and Antigen.
His Immunology study frequently links to other fields, such as In vitro.
Lieping Chen focuses mostly in the field of Cancer, narrowing it down to topics relating to Melanoma and, in certain cases, Oncology, Internal medicine, Nivolumab, Immune checkpoint and Blockade.
His Immunotherapy study combines topics in areas such as Cancer cell, Lung cancer and Survival analysis.
Between 2015 and 2021, his most popular works were:
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations (1028 citations)
- Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target (647 citations)
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization (378 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Immune system
His scientific interests lie mostly in Immunotherapy, Cancer research, Cancer, Immune system and Immunology.
He has included themes like Tumor microenvironment and Lung cancer, Oncology in his Immunotherapy study.
Lieping Chen interconnects Cell, T cell, Antigen, Carcinoma and CD3 in the investigation of issues within Cancer research.
His Cancer research incorporates themes from Cytotoxic T cell and Monoclonal antibody.
The various areas that Lieping Chen examines in his Immune system study include Antibody and Mediator.
Lieping Chen studies Immunology, focusing on Immune privilege in particular.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
